ASCO Reading Room | Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival
MedPage Today,
Arnon P. Kater, MD; John F. Seymour, MD; Peter Hillmen, MD; Barbara Eichhorst, MD; Anton W.